首页> 外文期刊>Seminars in pediatric surgery >Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies
【24h】

Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies

机译:神经母细胞瘤的最新生物学和遗传学进展:对诊断,风险分层和治疗策略的意义

获取原文
获取原文并翻译 | 示例
           

摘要

Neuroblastoma is an embryonic cancer of neural crest cell lineage, accounting for up to 10% of all pediatric cancer. The clinical course is heterogeneous ranging from spontaneous regression in neonates to life-threatening metastatic disease in older children. Much of this clinical variance is thought to result from distinct pathologic characteristics that predict patient outcomes. Consequently, many research efforts have been focused on identifying the underlying biologic and genetic features of neuroblastoma tumors in order to more clearly define prognostic subgroups for treatment stratification. Recent technological advances have placed emphasis on the integration of genetic alterations and predictive biologic variables into targeted treatment approaches to improve patient survival outcomes. This review will focus on these recent advances and the implications they have on the diagnostic, staging, and treatment approaches in modern neuroblastoma clinical management. (C) 2016 Elsevier Inc. All rights reserved.
机译:神经母细胞瘤是神经c细胞谱系的胚胎癌,占所有儿童癌症的10%。从新生儿的自然消退到大龄儿童的威胁生命的转移性疾病,临床过程是多种多样的。人们认为,大部分这种临床差异是由可预测患者预后的独特病理特征引起的。因此,许多研究工作已集中在鉴定神经母细胞瘤肿瘤的潜在生物学和遗传特征上,以便更清楚地定义治疗分层的预后亚组。最近的技术进步已将重点放在将遗传改变和预测性生物学变量整合到靶向治疗方法中以改善患者的生存结果。本文将重点关注这些最新进展及其对现代神经母细胞瘤临床管理中的诊断,分期和治疗方法的影响。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号